Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) Sees Significant Decrease in Short Interest

Allena Pharmaceuticals, Inc. (NASDAQ:ALNAGet Rating) was the target of a significant drop in short interest in the month of April. As of April 15th, there was short interest totalling 1,870,000 shares, a drop of 21.8% from the March 31st total of 2,390,000 shares. Based on an average daily volume of 1,680,000 shares, the short-interest ratio is currently 1.1 days.

Several hedge funds have recently bought and sold shares of the company. Virtu Financial LLC bought a new stake in Allena Pharmaceuticals during the fourth quarter worth $79,000. Kestra Advisory Services LLC lifted its holdings in Allena Pharmaceuticals by 53.8% during the fourth quarter. Kestra Advisory Services LLC now owns 161,500 shares of the company’s stock worth $96,000 after acquiring an additional 56,500 shares during the period. Spire Wealth Management lifted its holdings in Allena Pharmaceuticals by 83.9% during the fourth quarter. Spire Wealth Management now owns 91,940 shares of the company’s stock worth $54,000 after acquiring an additional 41,940 shares during the period. Altium Capital Management LP bought a new stake in Allena Pharmaceuticals during the third quarter worth $963,000. Finally, Jane Street Group LLC bought a new stake in Allena Pharmaceuticals during the third quarter worth $49,000. Institutional investors own 22.52% of the company’s stock.

A number of brokerages have commented on ALNA. B. Riley cut Allena Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $3.00 price objective for the company. in a research note on Tuesday, March 22nd. Zacks Investment Research raised Allena Pharmaceuticals from a “sell” rating to a “hold” rating and set a $0.25 price objective for the company in a research note on Wednesday, March 23rd. LADENBURG THALM/SH SH reissued a “neutral” rating on shares of Allena Pharmaceuticals in a research note on Monday, March 21st. Finally, HC Wainwright reissued a “neutral” rating on shares of Allena Pharmaceuticals in a research note on Monday, March 21st.

ALNA stock opened at $0.17 on Tuesday. Allena Pharmaceuticals has a twelve month low of $0.16 and a twelve month high of $1.45. The stock’s 50 day moving average is $0.32 and its 200-day moving average is $0.52. The firm has a market capitalization of $13.95 million, a PE ratio of -0.20 and a beta of 1.92.

Allena Pharmaceuticals (NASDAQ:ALNAGet Rating) last posted its earnings results on Thursday, March 31st. The company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.05. On average, research analysts expect that Allena Pharmaceuticals will post -0.77 EPS for the current year.

Allena Pharmaceuticals Company Profile (Get Rating)

Allena Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.

Read More

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.